Title: Reduction of Brain Glutathione by <scp>l</scp>‐Buthionine Sulfoximine Potentiates the Dopamine‐Depleting Action of 6‐Hydroxydopamine in Rat Striatum
Abstract: Abstract: Sprague‐Dawley rats were anesthetized with chloral hydrate, and plastic cannulae were permanently implanted into the lateral ventricles. The animals then were allowed to recover for 1–2 days. L‐Buthionine sulfoximine ( l ‐BSO), a selective inhibitor of glutathione (GSH) synthesis, and 6‐hydroxydopamine (6‐OH‐DA), a selective catecholaminergic neurotoxin, were administered intracerebroventricularly. The striatal concentrations of GSH and monoamines were determined by HPLC with electrochemical detection. Two injections of l ‐BSO (3.2 mg, at a 48‐h interval) resulted in a 70% reduction of striatal GSH. 6‐OH‐DA (150 or 300 μg) reduced the concentrations of striatal dopamine and noradrenaline 7 days after the administration, but left the concentrations of 5‐hydroxytryptamine unaltered. L‐BSO treatment did not produce any changes in the levels of monoamines per se but it potentiated the catecholamine‐depleting effect of 6‐OH‐DA in the striatum. Thus, GSH appears to suppress the toxicity of 6‐OH‐DA, probably by scavenging the toxic species formed during 6‐OH‐DA oxidation. In view of these results one may suggest an important role for GSH in catecholaminergic neurons: protecting against the oxidation of endogenous catechols.
Publication Year: 1989
Publication Date: 1989-03-01
Language: en
Type: article
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 86
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot